Mobia Medical, a commercial-stage company dedicated to advancing stroke recovery, has successfully priced its initial public offering to raise approximately $150 million. This significant financial milestone is poised to accelerate the commercialization of its innovative technology for patients living with severe motor impairments. The company's shares are set to begin trading on the Nasdaq Global Select Market, heralding a new era of growth and public visibility for its mission.
IPO Details and Market Debut
The Austin-based medical device firm officially announced the offering of 10,000,000 shares of its common stock at a public price of $15.00 per share. This public debut is scheduled for May 8, 2026, on the Nasdaq under the ticker symbol "MOBI," a significant step for the company. The offering is anticipated to formally close on May 11, 2026, subject to the satisfaction of customary closing conditions.
The IPO was managed by a consortium of prominent financial institutions, with BofA Securities, J.P. Morgan, and Goldman Sachs & Co. LLC acting as lead bookrunners. Furthermore, underwriters have been granted a 30-day option to purchase up to an additional 1,500,000 shares at the offering price. This option could potentially increase the total proceeds and reflects strong market confidence in the company's future prospects.
A New Chapter for Stroke Recovery
Mobia Medical is strategically focused on redefining therapeutic options for the many stroke survivors who experience debilitating, life-altering motor function loss. The company aims to address a significant unmet clinical need in the post-stroke care continuum with its pioneering solutions. Its core mission is to empower patients, providers, and caregivers by establishing a more effective and accessible standard of care.
At the heart of its innovative strategy is the Vivistim® Paired VNS™ System, the first and only FDA-approved implantable device of its kind. This unique system combines targeted vagus nerve stimulation with patient-led functional movement exercises to enhance neuroplasticity in the brain. The therapy is specifically designed to generate meaningful and lasting improvements in upper limb function for chronic ischemic stroke survivors.
Strategic Implications and Future Outlook
The substantial capital raised from this successful IPO is expected to fuel the company's commercial expansion and operational scale-up across key markets. These funds will be crucial for increasing market penetration of the Vivistim® system and making the therapy more accessible to the patients who need it most. Further investment in research and development to refine and expand its technology platform is also a key priority.
This successful public offering highlights growing investor confidence in the medical technology sector, particularly in the field of advanced neurorehabilitation innovations. Mobia Medical's strong entry into the public market could inspire further investment in novel solutions for chronic neurological conditions. The move ultimately promises to accelerate the delivery of advanced therapies to patients in desperate need of better recovery options.
Mobia Medical's impressive $150 million IPO represents a pivotal moment for the company and the broader field of stroke rehabilitation. With this significant new capital, the firm is now well-positioned to expand the reach of its groundbreaking Vivistim® system to more survivors. This public debut not only validates its innovative clinical approach but also signals a more hopeful future for patients seeking to regain critical motor function.